

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 60-72 are rejected under 35 U.S.C. § 103 as being unpatentable over Peyman in view of Eisenberg. Peyman teaches a system as claimed except for the particular light source and optical fiber material. Eisenberg teaches the desirability of using an Erbium laser for tissue repair ^{or} ~~en~~ removal. It would have been obvious to the artisan of ordinary skill to employ an ^{Er: YLF} ~~Erikle~~ laser to perform the surgery since ^{this} ~~there~~ is appropriate for tissue removal and repair, as taught by Eisenberg and to use ^{Holmium} ~~Helman~~, Erbium, and Thulium as the ^{lasing ions} ~~layering~~ core, since ^{these} ~~this~~ are known to produce wavelength the in the ranges disclosed by ^{Peyman} ~~Peperman~~, judicial notice of which is hereby taken, are equivalents, are not critical, and provide no unexpected result; to employ YLF or YAG as the crystal substrates, since these are widely used as substitutes for ^{lasing ions} ~~judicial notice of which is hereby taken are equivalent and produce~~

9B no unexpected result; to employ a ^{low}~~low~~ hydroxyl ^{ion}~~ion~~ content fiber,
9B since these were commercially available and known to ^{transmit}~~treatment~~ the
9B desired wavelength at the time of the ^{invention}~~conventions~~ and to employ the
claimed pulse width and repetition rates, since these are not
critical, are well known in the art, and would provide efficient
tissue removal or repair without excessive heating of surrounding
tissue for the disclosed irradiated area, judicial notice of which
are hereby taken, thus producing a device such as claimed.

9B Claims 60-72 are rejected under the judicially created
doctrine of obviousness-type double patenting as being unpatentable
over claims ^{1-4,}~~6-9,~~ and 15-41 of U.S. Patent No. 4,950,266. Although
the conflicting claims are not identical, they are not patentably
distinct from each other because it would have been obvious to
include various unclaimed structures (e.g. focussing lens at
9B ^{proximal}~~proximal~~ fiber ^{end}~~end~~ and diameter of surgical ^{site}~~site~~) as they are
9B ^{in the art}~~conventional~~ is thought, ^{thus}~~this~~ producing a device such as claimed.

9B Claims 60-72 are rejected under the judicially created
doctrine of obviousness-type double patenting as being unpatentable
over claims ^{1-16.}~~60-72~~ of U.S. Patent No. 4,917,084. Although the
conflicting claims are not identical, they are not patentably
distinct from each other because it would have been obvious to
include various unclaimed structures which are inherently necessary
(e.g. means for coupling the laser energy to the fiber) or
conventional (e.g. means attached to the distal end of the fiber
directing the laser energy ...) thus providing a device such as

Serial No. 411,581
Art Unit 3311

-4-

claimed.


Claims 60-72 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-32 of U.S. Patent No. 5,196,004. Although the conflicting claims are not identical, they are not patentably distinct from each other because of substantially same ^{reasons} ~~reasons~~ set forth in the double patenting rejection concerning U.S. Patent number 4,950,266.

JB The obviousness-type double patenting rejection is a judicially established doctrine based upon public policy and is primarily intended to prevent prolongation of the patent term by prohibiting claims in a second patent not patentably distinct from claims in a first patent. *In re Vogel*, 164 USPQ 619 (CCPA 1970). A timely filed terminal disclaimer in compliance with 37 C.F.R. § 1.321(b) would overcome an actual or provisional rejection on this ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 C.F.R. § 1.78(d).

The claims are additionally rejected under non-statutory, no obviousness type double patenting over the claims and patents set forth above as set forth in *In re Schneller* 397 F. 2d 350, 158 USPQ 210 (CCPA 1962).

Any inquiry concerning this communication should be directed to David Shay at telephone number (703) 308-2215.

David Shay:bhw
July 2, 1997


JENNIFER BAHR
PRIMARY EXAMINER
GROUP 3300